Suppr超能文献

一项关于优化体重管理干预措施的随机对照评估试验的EVO研究方案。

The EVO study protocol for a randomized controlled evaluation trial of an optimized weight management intervention.

作者信息

Pfammatter Angela Fidler, Battalio Samuel L, Olvera Charlie, DeZelar Margaret, Moore Dominique, Scanlan Laura, Siddique Juned, Spring Bonnie, Chang Su-Hsin

机构信息

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

出版信息

Contemp Clin Trials. 2022 May;116:106750. doi: 10.1016/j.cct.2022.106750. Epub 2022 Apr 1.

Abstract

BACKGROUND

Obesity is a substantial public health concern; however, gold-standard behavioral treatments for obesity are costly and burdensome. Existing adaptations to the efficacious Diabetes Prevention Program (DPP) demonstrate mixed results. Our prior research applying the Multiphase Optimization Strategy (MOST) to DPP identifies a more parsimonious, less costly intervention (EVO) resulting in significant weight loss.

OBJECTIVE

The aim of the remotely conducted EVO trial is to test the non-inferiority of EVO against DPP. We will conduct economic evaluations alongside the trial to estimate delivery and patient costs, cost-effectiveness, and lifetime healthcare costs of EVO as compared to DPP. Exploratory analyses will examine maintenance, moderators, and mediators of the treatment effect.

STUDY DESIGN

The EVO trial will recruit nationally to randomize 524 participants with obesity. Participants will receive either EVO or DPP over a 6 month period. EVO participants will be provided online lessons, a smartphone application to self-monitor diet, physical activity, and weight, and attend 12 brief calls with a Health Promotionist. DPP participants will receive the first 6 months of the Center for Disease Control's T2D materials and attend 16 one-hour video call sessions with staff certified in DPP delivery. Weight will be measured at baseline, 3-, 6-, and 12-months. Itemized delivery cost will be collected. Staff and participants will also provide information to estimate costs for intervention-related activities.

SIGNIFICANCE

The EVO trial could establish evidence supporting dissemination of a scalable, cost-effective behavioral treatment with potential to shift clinical practice guidelines, inform policy, and reduce the prevalence of obesity.

摘要

背景

肥胖是一个重大的公共卫生问题;然而,肥胖的金标准行为治疗成本高昂且负担沉重。对有效的糖尿病预防计划(DPP)的现有改编效果不一。我们之前将多阶段优化策略(MOST)应用于DPP的研究确定了一种更简约、成本更低的干预措施(EVO),该措施能带来显著的体重减轻。

目的

远程进行的EVO试验旨在测试EVO相对于DPP的非劣效性。我们将在试验过程中进行经济评估,以估计EVO与DPP相比的实施成本和患者成本、成本效益以及终身医疗成本。探索性分析将研究治疗效果的维持情况、调节因素和中介因素。

研究设计

EVO试验将在全国范围内招募524名肥胖参与者进行随机分组。参与者将在6个月内接受EVO或DPP治疗。EVO组参与者将获得在线课程、一款用于自我监测饮食、身体活动和体重的智能手机应用程序,并与一名健康促进员进行12次简短通话。DPP组参与者将获得疾病控制中心2型糖尿病材料的前6个月内容,并参加16次与经DPP培训认证的工作人员进行的一小时视频通话课程。将在基线、3个月、6个月和12个月时测量体重。收集详细的实施成本。工作人员和参与者还将提供信息以估计与干预相关活动的成本。

意义

EVO试验可以建立证据,支持推广一种可扩展、具有成本效益的行为治疗方法,这种方法有可能改变临床实践指南、为政策提供信息并降低肥胖的患病率。

相似文献

本文引用的文献

8
Why primary obesity is a disease?为什么原发性肥胖是一种疾病?
J Transl Med. 2019 May 22;17(1):169. doi: 10.1186/s12967-019-1919-y.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验